At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,798 enrolled
Drug / intervention
Nintedanibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Economic Burden Associated With Nintedanib Non-adherence Among Medicare Beneficiaries With IPF
In Brief
An observational study evaluating Nintedanib for Idiopathic Pulmonary Fibrosis. Completed, enrolled 1,798 participants across 1 site.
Detailed Summary
This study has two objectives: 1. To assess the association between nintedanib adherence trajectory group (as measured from a Group-based Trajectory Modelling (GBTM)) and health care resource use, with a focus on inpatient hospitalization, among patients with Idiopathic Pulmonary Fibrosis (IPF). 2. To assess the association between a patient's nintedanib adherence trajectory group (as measured from a GBTM) and their medical costs among patients with IPF.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Pulmonary Fibrosis
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
202420252026
Enrollment StartMay 2023
First PostedMay 2023
Primary CompletionJun 2023
TodayJul 2026
First PostedMay 23, 2023
Enrollment StartMay 16, 2023
Primary CompletionJun 30, 2023
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 3.1 years ago
Interventions
Nintedanibdrug
Nintedanib